Stocks · News reference

IGC Pharma Says CEO Ram Mukunda And Principal Financial Officer Claudia Grimaldi Purchase Aggregate Of 4,274,853 Shares Directly From Company At $0.27/Shr

Jul 7, 2026, 1:03 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 28, 2026, 5:49 PMBenzinga Newsdesk
President And Founder Of Seabreeze Capital Partners LP Dougie Kass Posts On X "We have moved to super size $MSOS and individual cannabis stocks in the belief that a favorable rescheduling announcement will come shortly."
https://x.com/DougKass/status/2093394146182480247
ACB AKAN CGC CRON GRWG
BenzingaAug 26, 2026, 9:55 AMBenzinga Newsdesk
Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $6
Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $5.5 to $6.
IGC
BenzingaAug 17, 2026, 12:40 PMBenzinga Newsdesk
IGC Pharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $265.000K Beat $258.000K Estimate
IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 50 percent decrease over losses of $(0.02) per share from the same
IGC
BenzingaAug 11, 2026, 12:36 PMBenzinga Newsdesk
IGC Pharma Says Phase 2 CALMA Trial Of IGC-AD1 In Alzheimer's Agitation Has Randomized 160 Participants To Date, With Topline Results Expected In Q4 2026
IGC